| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.35 | 0.02 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.099 | 0.02 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | -0.099 | 0.03 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |